statement
Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.
A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
한올바이오파마의 파트너사 이뮤노반트가 진행한 IMVT-1402의 난치성 류마티스 관절염(D2T RA) 임상 2b상에서 뛰어난 효능과 안전성이 입증되며 개발 전략의 타당성을 확보했다.
Related claims
Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statementIn the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementLG Chem signed a revised license agreement with Rhythm Pharmaceuticals for Bivamelagon on November 3, expanding total contract value from $305 million to $855 million.LG화학 · statement에피노페그듀타이드 10mg은 섬유화 개선 외 모든 항목에서 통계적 유의성을 충족했고, 보수적인 mITT 분석에서도 의미 있는 결과를 보였다.하나증권 · statement